Decision Resources, Inc.

Atypical antipsychotics will drive the schizophrenia drug market

Published in Pharma Investments, Ventures and Law Weekly, July 18th, 2004

Decision Resources, Inc., finds that although more-expensive atypical antipsychotics such as Eli Lilly's Zyprexa, Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify, Janssen's Risperdal, AstraZeneca's Seroquel, and Pfizer's Geodon will drive the schizophrenia drug market during the period 2003-2013, they will face generic competition by the end of this time frame.

According to a new Pharmacor study entitled Schizophrenia, generic erosion will exact a heavy toll on the market because these antipsychotics lose patent protection in 2007 or later.

"Generics will have the greatest impact on the U.S. market, which is the largest and most receptive market...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2004-07-18)

More Articles from Pharma Investments, Ventures and Law Weekly

Advanced Medical Optics, Inc.
Ophthalmic surgical device maker reports preliminary 2005 guidance
BioLineRx
Israeli pharmaceutical firm completes management team
Biophan Technologies, Inc.
Financing option to be discussed at meeting by device firm
Business & Finance
I-trax awarded first health system contract for population health management
Business & Finance
Walgreens purchases Osco patient prescription records
Calypte Biomedical Corporation
Device maker files registration statement for sale of stock
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry